title: Copper-mediated LDL oxidation by homocysteine and related compounds depends largely on copper ligation.
abstract: Oxidation of low-density lipoprotein (LDL) is thought to be a major factor in the pathophysiology of atherosclerosis. Elevated plasma homocysteine is an accepted risk factor for atherosclerosis, and may act through LDL oxidation, although this is controversial. In this study, homocysteine at physiological concentrations is shown to act as a pro-oxidant for three stages of copper-mediated LDL oxidation (initiation, conjugated diene formation and aldehyde formation), whereas at high concentration, it acts as an antioxidant. The affinity for copper of homocysteine and related copper ligands homocysteine, cystathionine and djenkolate was measured, showing that at high concentrations (100 microM) under our assay conditions, they bind essentially all of the copper present. This is used to rationalise the behaviour of these ligands, which stimulate LDL oxidation at low concentration but generally inhibit it at high concentration. Albumin strongly reduced the effect of homocystine on lag time for LDL oxidation, suggesting that the effects of homocystine are due to copper binding. In contrast, copper binding does not fully explain the pro-oxidant behaviour of low concentrations of homocysteine towards LDL, which appears in part at least to be due to stimulation of free radical production. The likely role of homocysteine in LDL oxidation in vivo is discussed in the light of these results.
authors.affiliation: Centre for Human Nutrition, Division of Clinical Sciences, University of Sheffield, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.
authors.forename: Emi
authors.initials: E
authors.lastname: Nakano
authors.forename: Mike P
authors.initials: MP
authors.lastname: Williamson
authors.forename: Nick H
authors.initials: NH
authors.lastname: Williams
authors.forename: Hilary J
authors.initials: HJ
authors.lastname: Powers
mesh_terms: D003300:Copper / Q000737:chemistry*; D003540:Cystathionine / Q000494:pharmacology; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006710:Homocysteine / Q000032:analysis / Q000737:chemistry* / Q000494:pharmacology; D006711:Homocystine / Q000494:pharmacology; D006801:Humans; D008077:Lipoproteins, LDL / Q000737:chemistry* / Q000302:isolation & purification; D008315:Malondialdehyde / Q000737:chemistry; D010084:Oxidation-Reduction / Q000187:drug effects; D012709:Serum Albumin / Q000494:pharmacology; D013997:Time Factors
chemical_list: D008077:Lipoproteins, LDL; D012709:Serum Albumin; D006710:Homocysteine; D003540:Cystathionine; C004851:djenkolic acid; D006711:Homocystine; D008315:Malondialdehyde; D003300:Copper; D003545:Cysteine